These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 29552327)

  • 1. Who will benefit more from maintenance therapy of metastatic colorectal cancer?
    Zhou M; Fu L; Zhang J
    Oncotarget; 2018 Feb; 9(15):12479-12486. PubMed ID: 29552327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is FOLFOXIRI alone or combined with targeted therapy administered as first-line treatment a reasonable choice for most patients with mCRC? Systematic review and network meta-analysis.
    Zhou M; Yu P; Hernick Davin DB; Li Y; Wang Y; Fu L; Zhang J
    Oncotarget; 2017 Sep; 8(37):62339-62348. PubMed ID: 28977949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Role of Maintenance Strategies in Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis of Randomized Clinical Trials.
    Sonbol MB; Mountjoy LJ; Firwana B; Liu AJ; Almader-Douglas D; Mody K; Hubbard J; Borad M; Ahn DH; Murad MH; Bekaii-Saab T
    JAMA Oncol; 2020 Mar; 6(3):e194489. PubMed ID: 31855256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Bevacizumab in the First-Line Treatment of Patients with RAS Mutations Metastatic Colorectal Cancer: a Systematic Review and Network Meta-Analysis.
    Zhou M; Yu P; Qu J; Chen Y; Zhou Y; Fu L; Zhang J
    Cell Physiol Biochem; 2016; 40(1-2):361-369. PubMed ID: 27866194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The addition of bevacizumab in the first-line treatment for metastatic colorectal cancer: an updated meta-analysis of randomized trials.
    Jang HJ; Kim BJ; Kim JH; Kim HS
    Oncotarget; 2017 Sep; 8(42):73009-73016. PubMed ID: 29069844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Application and Intensity of Bevacizumab-based Maintenance After Induction Chemotherapy With Bevacizumab for Metastatic Colorectal Cancer: A Meta-analysis.
    Stein A; Schwenke C; Folprecht G; Arnold D
    Clin Colorectal Cancer; 2016 Jun; 15(2):e29-39. PubMed ID: 26781523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy and safety of panitumumab in the treatment of patients with metastatic colorectal cancer: a meta-analysis from five randomized controlled trials.
    Liang RF; Zheng LL
    Drug Des Devel Ther; 2015; 9():4471-8. PubMed ID: 26300630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial.
    Tournigand C; Chibaudel B; Samson B; Scheithauer W; Vernerey D; Mésange P; Lledo G; Viret F; Ramée JF; Tubiana-Mathieu N; Dauba J; Dupuis O; Rinaldi Y; Mabro M; Aucoin N; Latreille J; Bonnetain F; Louvet C; Larsen AK; André T; de Gramont A
    Lancet Oncol; 2015 Nov; 16(15):1493-1505. PubMed ID: 26474518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab in combination with first-line chemotherapy in patients with metastatic colorectal cancer: a meta-analysis.
    Hu W; Xu WS; Liao XF; He HJ
    Minerva Chir; 2015 Dec; 70(6):451-8. PubMed ID: 26013763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
    Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Al-Batran SE; Lange T; Dietrich G; Stoehlmacher J; Tannapfel A; Reinacher-Schick A; Quidde J; Trarbach T; Hinke A; Schmoll HJ; Arnold D
    Lancet Oncol; 2015 Oct; 16(13):1355-69. PubMed ID: 26361971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a meta-analysis.
    Wang M; Zheng X; Ruan X; Ye B; Cai L; Lin F; Tu J; Jiang F; Li S
    Chin Med J (Engl); 2014; 127(3):538-46. PubMed ID: 24451964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy and safety of bevacizumab combined with chemotherapy in treatment of HER2-negative metastatic breast cancer: a meta-analysis based on published phase III trials.
    Fang Y; Qu X; Cheng B; Chen Y; Wang Z; Chen F; Xiong B
    Tumour Biol; 2015 Mar; 36(3):1933-41. PubMed ID: 25387808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Doublet chemotherapy vs. single-agent therapy with 5FU in elderly patients with metastatic colorectal cancer. a meta-analysis.
    Landre T; Uzzan B; Nicolas P; Aparicio T; Zelek L; Mary F; Taleb C; Des Guetz G
    Int J Colorectal Dis; 2015 Oct; 30(10):1305-10. PubMed ID: 26099322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A network meta-analysis on the efficacy of sixteen targeted drugs in combination with chemotherapy for treatment of advanced/metastatic colorectal cancer.
    Ba-Sang DZ; Long ZW; Teng H; Zhao XP; Qiu J; Li MS
    Oncotarget; 2016 Dec; 7(51):84468-84479. PubMed ID: 27806321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind, randomized, placebo-controlled, phase 2 study of maintenance enzastaurin with 5-fluorouracil/leucovorin plus bevacizumab after first-line therapy for metastatic colorectal cancer.
    Wolff RA; Fuchs M; Di Bartolomeo M; Hossain AM; Stoffregen C; Nicol S; Heinemann V
    Cancer; 2012 Sep; 118(17):4132-8. PubMed ID: 22213153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefit of Bevacizumab-Based Frontline Therapy in Patients with Metastatic Colorectal Cancer (mCRC): a Turkish Oncology Group Study.
    Artaç M; Coşkun HŞ; Dane F; Karabulut B; Korkmaz L; Karaağaç M; Çabuk D; Karabulut S; Faruk Aykan N; Doruk H; Avcı N; Turhal NS
    J Gastrointest Cancer; 2016 Sep; 47(3):264-72. PubMed ID: 27126591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial.
    Greil R; Obrtlíková P; Smolej L; Kozák T; Steurer M; Andel J; Burgstaller S; Mikušková E; Gercheva L; Nösslinger T; Papajík T; Ladická M; Girschikofsky M; Hrubiško M; Jäger U; Fridrik M; Pecherstorfer M; Králiková E; Burcoveanu C; Spasov E; Petzer A; Mihaylov G; Raynov J; Oexle H; Zabernigg A; Flochová E; Palášthy S; Stehlíková O; Doubek M; Altenhofer P; Pleyer L; Melchardt T; Klingler A; Mayer J; Egle A
    Lancet Haematol; 2016 Jul; 3(7):e317-29. PubMed ID: 27374465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
    Simkens LH; van Tinteren H; May A; ten Tije AJ; Creemers GJ; Loosveld OJ; de Jongh FE; Erdkamp FL; Erjavec Z; van der Torren AM; Tol J; Braun HJ; Nieboer P; van der Hoeven JJ; Haasjes JG; Jansen RL; Wals J; Cats A; Derleyn VA; Honkoop AH; Mol L; Punt CJ; Koopman M
    Lancet; 2015 May; 385(9980):1843-52. PubMed ID: 25862517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of complete chemotherapy stop on the overall survival of patients with advanced colorectal cancer in first-line setting: A meta-analysis of randomized trials.
    Pereira AA; Rego JF; Munhoz RR; Hoff PM; Sasse AD; Riechelmann RP
    Acta Oncol; 2015 Nov; 54(10):1737-46. PubMed ID: 25984931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials.
    Kabbinavar FF; Hurwitz HI; Yi J; Sarkar S; Rosen O
    J Clin Oncol; 2009 Jan; 27(2):199-205. PubMed ID: 19064978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.